Clinical Trial Update: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Glembatumumab Vedotin (CDX-011) in metastatic gpNMB-overexpressing triple-negative breast cancer has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-03-08